Malignant pericardial effusion

Cardiology (Switzerland)

Volumn 124, Issue 4, 2013, Pages 224-232

  Burazor, I ^a   Imazio, M ^b   Markel, G ^c,d   Adler, Y ^c,d  

^a CLINICAL CENTER NI   (Serbia)

^b MARIA VITTORIA HOSPITAL   (Italy)

^c SHEBA MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antineoplastic therapies; Malignant pericardial effusion; Pericardiocentesis

Indexed keywords

ACLARUBICIN; ALBINTERFERON ALPHA2B; ARSENIC TRIOXIDE; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; IMATINIB; INTERLEUKIN 2; MITOXANTRONE; PHOSPHORUS 32; PLATINUM DERIVATIVE; RETINOIC ACID; THIOTEPA; ALPHA2B INTERFERON;

ACUTE PROMYELITIC LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONSTRICTIVE PERICARDITIS; DIAGNOSTIC IMAGING; DYSPNEA; ELECTROCARDIOGRAPHY; ESOPHAGUS CANCER; HEART CATHETERIZATION; HEART FAILURE; HEART TAMPONADE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LUNG CANCER; LYMPHOMA; MALIGNANT PERICARDIAL EFFUSION; METASTASIS; MYOCARDITIS; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PERICARDIOTOMY; PERICARDITIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENT DISEASE; RESPIRATORY TRACT CANCER; REVIEW; SOLID TUMOR; STOMACH CANCER; SURGICAL DRAINAGE; SYMPTOMATOLOGY; THORAX SURGERY; THYMOMA; TREATMENT PLANNING; CANCER RECURRENCE; DRAINAGE CATHETER; ECHOCARDIOGRAPHY; EFFUSIVE CONSTRICTIVE PERICARDITIS; HEART CANCER; PERICARDIUM;

DIAGNOSTIC IMAGING; ELECTROCARDIOGRAPHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASM METASTASIS; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PERICARDIAL EFFUSION; PERICARDITIS, CONSTRICTIVE; PHYSICAL EXAMINATION; PROGNOSIS; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84875861335     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000348559     Document Type: Review

References (49)

1. Halfdanarson TR, Hogan WJ, Moynihan TJ: Oncologic emergencies: diagnosis and treatment. Mayo Clin Proc 2006; 81: 835-848.
2. Kim SH, Kwak MH, Park S, Kim HJ, Lee HS, Kim MS, Lee JM, Zo JI, Ro JS, Lee JS: Clinical characteristics of malignant pericardial effusion associated with recurrence and survival. Cancer Res Treat 2010; 42: 210-216
3. Karatolios KAlter P, Maisch B: Differentiation of malignant from nonmalignant, inflammatory pericardial effusions with biomarkers. Herz 2009; 34: 624-633.
4. Jeong TD, Jang S, Park CJ, Chi HS: Prognostic relevance ofpericardial effusion in patients with malignant diseases. Korean J Hematol 2012; 47: 237-238.
5. Refaat M, Katz W: Neoplastic pericardial effusion. Clin Cardiol 2011; 34: 593-598.
6. Galderisi M, Marra F, Esposito R, Lomoriello V, Pardo M, de Divitiis O: Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography. Cardiovasc Ultrasound 2007; 5: 4
7. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT: Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9: 1215-1223.
8. Dow E, Schulman H, Agura E: Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant 1993; 12: 169-172.
9. Gottdiener JSAppelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J: Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-763.
10. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr: The retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-296.
11. Soignet SL: Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 2001; 6(suppl 2):11-16.
12. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E; International STI571 CML Study Group: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
13. Bomford CK, Kunkler IH (eds): Walter and Miller's Textbook of Radiotherapy: Radiation Physics, Therapy and Oncology. Edinburgh, Churchill Livingstone, 2002.
14. Perrault DJ, Levy M, Herman JD, Burns RJ, Bar Shlomo BZ, Druck MN, Wu WQ, McLaughlin PR, Gilbert BW: Echocardiographic abnormalities following cardiac radiation. J Clin Oncol 1985; 3: 546-551.
15. Pohjola-Sintonen S, Totterman KJ, Salmo M, Siltanen P: Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin's disease. Cancer 1987; 60: 31-37.
16. Imazio M, Mayosi B, Brucato A, Markerl G, Trinchero R, Spodick D, Adler Y: Triage and management of pericardial effusion. J Cardiovasc Med 2010; 11: 928-935.
17. Jneid H, Maree AO, Palacios I: Pericardial tamponade: clinical presentation, diagnosis and catheter-based therapies; in Parrillo JE, Dellinger RP (eds): Critical Care Medicine: Principles of Diagnosis & Management in the Adult, ed 3. Philadelphia, Mosby, 2007.
18. D'Cruz I, Rehman AU, Hancock HL: Quantitative echocardiographic assessment in pericardial disease. Echocardiography 1997; 14: 207-214.
19. Verhaert D, Gabriel R, Johnston D, Lytle B, Desai M, Klein A: The role of multimodality imaging in the management of pericardial disease. Circ Cardiovasc Imaging 2010; 3: 333-343.
20. Rajiah P: Cardiac MRI. 2. Pericardial diseases. AJR Am J Roentgenol 2011; 197:W621-W634.
21. Talreja DR, Nishimura RA, Oh JK, Holmes DR: Constrictive pericarditis in the modern era: novel criteria for diagnosis in the cardiac catheterization laboratory. J Am Coll Cardiol 2008; 51: 315-319.
22. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marmé D, Gastl G: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999; 85: 178-187.
23. Maisch B, Ristic A, Pankuweit S:Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis 2010; 53: 157-163.
24. Karatolios K, Maisch B, Pankuweit S: Tumor markers in the assessment of malignant and benign pericardial effusion. Herz 2011; 36: 290-295.
25. Karatolios K, Pankuweit S, Moosdorf RG, Maisch B: Vascular endothelial growth factor in malignant and benign pericardial effusion. Clin Cardiol 2012; 35: 377-381.
26. Takahashi H, Shibuya M: The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005; 109: 227-241.
27. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HFSenger DR, Connolly JL, Schnitt SJ: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86-91.
28. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993; 143: 1255-1262.
29. Karatolios K, Pankuweit S, Maisch B: Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion. Heart Fail Rev 2012, E-pub ahead of print.
30. Ristic AD, Pankuweit S, Maksimoviæ R, Moosdorf R, Maisch B: Pericardial cytokines in neoplastic, autoreactive, and viral pericarditis. Heart Fail Rev 2012, E-pub ahead of print.
31. Imazio M, Brucato A, Myosi B, Derosa F. G, Lestuzzi C, Macor A, Trinchero R, Spodick D, Adler Y: Medical therapy of pericardial disease. II. Noninfectious pericarditis, pericardia effusion and contrictive pericarditis. J Cardiovasc Med (Hagerstown) 2010; 11: 785-794.
32. Atar S, Chiu J, Forrester J, Siegel R: Bloody pericardial effusion in patients with cardiac tamponade. Chest 1999; 116: 1564-1569.
33. Tsang TS, Enriquez-Sarano M, Freeman WK, Barnes ME, Sinak LJ, Gersh BJ, Bailey KR, Seward JB: Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc 2002; 77: 429-436.
34. Gornik H, Gerhard-Herman M, Beckman J: Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol 2005; 23: 5211-5216.
35. Imazio M, Brucato A, Cumetti D, Brambilla G, Demichelis B, Ferro S, Maestroni S, Cecchi E, Belli R, Palmieri G, Trinchero R: Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation. Circulation 2008; 118: 667-671.
36. Levy PY, Moatti JP, Gauduchon V, Vandenesch F, Habib G, Raoult D: Comparison of intuitive versus systematic strategies for aetiological diagnosis of pericardial effusion. Scand J Infect Dis 2005; 37: 216-220.
37. Levy PY, Fournier PE, Charrel R, Metras D, Habib G, Raoult D: Molecular analysis of pericardial fluid: a 7-year experience. Eur Heart J2006; 27: 1942-1946.
38. Kunitoh H, Tamura T, Shibata T, Imai M, Nishiwaki Y, Nishio M, Yokoyama A, Watanabe K, Noda K, Saijo N: A randomized trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer. Br J Cancer 2009; 100: 464-469.
39. Van der Gaast A, Kok TC, van der Linden NH, Splinter TA: Intrapericardial instillation of bleomycin inthe management of malignant pericardial effusion. Eur J Cancer Clin Oncol 1989; 25: 1505-1506.
40. Lestuzzi C, Lafaras C, Bearz A, Gralec R, Viel E, Buonadonna A, Bischiniotis T: Malignant pericardial effusion: sclerotherapy or local chemotherapy Br J Cancer 2009; 101: 734-735.
41. Imazio M, Cecchi E, Demichelis B, Ierna S, Demarie D, Ghisio A, Pomari F, Coda L, Belli R, Trinchero R: Indicators of poor prognosis of acute pericarditis. Circulation 2007; 115: 2739-2744.
42. Maisch B, Seferovic PM, Ristic AD, Erbel R, Rienmuller R, Adler Y, Tomkowski WZ, Thiene G, Yacoub MH; Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology: Guidelines on the diagnosis and management of pericardial diseases executive summary. Eur Heart J 2004; 25: 587-610.
43. Dempke W, Firusian N: Treatment of malignant pericardial effusion with 32 P-colloid. Br J Cancer 1999; 80: 1955-1957.
44. Martini N, Freiman AH, Watson RC, Hilaris BS: Intrapericardial installation of radioactive chromic phosphate in malignant effusion. Am J Roentgenol 1977; 128: 639-664.
45. Lestuzzi C, Bearz A, Lafaras C, Gralec R, Cervesato E, Tomkowski W, DeBiasio M, Viel E, Bishiniotis T, Platogiannis DN, Buonadonna A, Tartuferi L, Piazza R, Tumolo S, Berretta M, Santini F, Imazio M: Neoplastic pericardial disease in lung cancer: impact on outcomes of different treatment strategies. A multicenter study. Lung Cancer 2011; 72: 340-347.
46. Mann T, Brodie BR, Grossman W, McLaurin L: Effusive-constrictive hemodynamic pattern due to neoplastic involvement of the pericardium. Am J Cardiol 1978; 41: 781-786.
47. Tsang TS, Seward JB, Barnes ME, Bailey KR, Sinak LJ Urban LH, Hayes SN: Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy. Mayo Clin Proc 2000; 75: 248-253.
48. García-Riego A, Cuinas C, Vilanova JJ: Malignant pericardial effusion. Acta Cytol 2001; 45: 561-566.
49. Dequanter D, Lothaire P, Berghmans T, Sculier JP: Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival. Ann Surg Oncol 2008; 15: 3268-3271.